Bristol-Myers Squibb

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Bristol-Myers Squibb 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About BMY

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers small molecules, products produced from biological processes called biologics, and chimeric antigen receptor (CAR-T) cell therapies. 

CEO
Christopher S. Boerner
CEOChristopher S. Boerner
Employees
32,500
Employees32,500
Headquarters
Princeton, New Jersey
HeadquartersPrinceton, New Jersey
Founded
1933
Founded1933
Employees
32,500
Employees32,500

BMY Key Statistics

Market cap
119.63B
Market cap119.63B
Price-Earnings ratio
13.16
Price-Earnings ratio13.16
Dividend yield
4.20%
Dividend yield4.20%
Average volume
14.36M
Average volume14.36M
High today
$59.87
High today$59.87
Low today
$58.44
Low today$58.44
Open price
$59.40
Open price$59.40
Volume
3.86M
Volume3.86M
52 Week high
$68.64
52 Week high$68.64
52 Week low
$42.52
52 Week low$42.52

Stock Snapshot

With a market cap of 119.63B, Bristol-Myers Squibb(BMY) trades at $58.57. The stock has a price-to-earnings ratio of 13.16 and currently yields dividends of 4.20%.

On 2026-10-19, Bristol-Myers Squibb(BMY) stock traded between a low of $58.44 and a high of $59.87. Shares are currently priced at $58.57, which is +0.2% above the low and -2.2% below the high.

Bristol-Myers Squibb(BMY) shares are trading with a volume of 3.86M, against a daily average of 14.36M.

During the past year, Bristol-Myers Squibb(BMY) stock moved between $42.52 at its lowest and $68.64 at its peak.

During the past year, Bristol-Myers Squibb(BMY) stock moved between $42.52 at its lowest and $68.64 at its peak.

BMY News

Fortune 4h
Companies are cashing in on AI productivity gains. Some bosses think workers deserve a cut - Fortune

...

Companies are cashing in on AI productivity gains. Some bosses think workers deserve a cut - Fortune
The Motley Fool 3d
Bristol-Myers Squibb vs. Johnson & Johnson: Which Healthcare Stock Is a Better Buy in 2026?

Healthcare remains a cornerstone for long-term investors, but choosing between a pure-play drugmaker and a diversified conglomerate is difficult. Is Bristol-Mye...

Bristol-Myers Squibb vs. Johnson & Johnson: Which Healthcare Stock Is a Better Buy in 2026?
Simply Wall St 5d
Why Bristol-Myers Squibb Is Back In The Spotlight

Bristol-Myers Squibb (BMY) is back in focus after reporting positive Phase 3 data for two late stage drugs: RYZ101 in gastroenteropancreatic neuroendocrine tumo...

Why Bristol-Myers Squibb Is Back In The Spotlight

Analyst ratings

58%

of 31 ratings
Buy
35.5%
Hold
58.1%
Sell
6.5%

More BMY News

TipRanks 7d
Risk-Reward Unfavorable for Bristol-Myers Squibb: Sell Rating Reiterated with Unchanged $41 Price Target

Morgan Stanley analyst Terence Flynn maintained a Sell rating on Bristol-Myers Squibb today and set a price target of $41.00. Terence Flynn has given his Sell...

People also own

Based on the portfolios of people who own BMY. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.